Jennifer Lund
University of North Carolina at Chapel Hill, NC·Public Health & Epidemiology
Clinical trials have shown that yearly lung cancer screening with low-dose computed tomography (CT), a type of X-ray scan, can greatly reduce deaths from lung cancer. Screening also brings harms, such as false alarms and complications from follow-up procedures.
- Fields
Public Health & Epidemiology
Mathematics & Statistics
Medicine & Clinical Research
- Topics
lung cancer
low-dose computed tomography
cancer screening
- Grants
- 1 known grant, through Jun 2028
What they work on
- Estimate the real-world benefits and harms of low-dose CT lung cancer screening among people eligible for screening, using trial transport to adjust National Lung Screening Trial results to national survey populations.
- Compare benefits and harms among people who are screened versus those who stay up to date with yearly screening, using target trial emulation with Medicare claims and the North Carolina Lung Screening Registry.
- Generate evidence on screening net benefit that accounts for selective drop-off along the screening process, to inform screening guidelines and shared decision-making tools.
More about the research
But people screened in everyday practice often differ from trial volunteers. Only about 10–20% of eligible people get screened, and only 40–60% of those stay up to date a year later. Because benefits and harms vary between groups, the real-world balance may differ from what the trials showed.
Why it matters
Better estimates of how lung cancer screening performs outside trials could help policymakers update screening recommendations and improve decision aids that doctors use to discuss benefits and harms with patients. This could support better delivery of lung cancer screening for older adults with smoking histories and others eligible for screening across the United States.
Known grants
From NIH and NSF research grants. Labs often have other funding we can't see.
Closest labs
Dominique Michaud
Tufts University, MA·Public Health & Epidemiology
Develop a pre-screening tool using blood leukocyte DNA methylation markers to sort high-risk NLST participants into finer risk categories and reduce the number of low-dose CT scans needed.
Sarah Robertson
Dartmouth College, NH·Public Health & Epidemiology·Early-career
Transport the effects of lung cancer screening strategies from trials such as NLST to nationally representative target populations by combining information from claims, registries, and studies.
Iakovos Toumazis
University of Texas MD Anderson Cancer Center, TX·Medicine & Clinical Research
Expand the ENGAGE lung cancer screening framework beyond age, sex and smoking history to include non-smoking risk factors such as race, family history and history of pulmonary disease.
The school
University of North Carolina at Chapel Hill: 72 labs on PI Pages, $1.6B a year on research, 523 research doctorates a year.
Reach out
A start for your email. Fill in the brackets.